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ABSTRACT
Proliferation and survival of chronic lymphocytic leukemia (CLL) cells depend 
on microenvironmental signals coming from lymphoid organs. One of the key players 
involved in the crosstalk between CLL cells and the microenvironment is the B-cell 
receptor (BCR). Syk protein, a tyrosine kinase essential for BCR signaling, is therefore 
a rational candidate for targeted therapy in CLL. Against this background, we tested 
the efficacy of the highly specific Syk inhibitor TAK-659 in suppressing the favorable 
signaling derived from the microenvironment. To ex vivo mimic the microenvironment 
found in the proliferation centers, we co-cultured primary CLL cells with BM stromal 
cells (BMSC), CD40L and CpG ODN along with BCR stimulation. In this setting, TAK-659 
inhibited the microenvironment-induced activation of Syk and downstream signaling 
molecules, without inhibiting the protein homologue ZAP-70 in T cells. Importantly, 
the pro-survival, proliferative, chemoresistant and activation effects promoted by the 
microenvironment were abrogated by TAK-659, which furthermore blocked CLL cell 
migration toward BMSC, CXCL12, and CXCL13. Combination of TAK-659 with other BCR 
inhibitors showed synergistic effect in inducing apoptosis, and the sequential addition 
of TAK-659 in ibrutinib-treated CLL cells induced significantly higher cytotoxicity. These 
findings provide a strong rationale for the clinical development of TAK-659 in CLL.
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is 
characterized by the expansion of monoclonal, mature 
CD5+/CD23+ B cells in the peripheral blood (PB) [1], 
secondary lymphoid tissues, and the bone marrow (BM).
In this microenvironment CLL cells receive survival, 
proliferation and drug resistance signals from accessory 
cells and soluble factors [2]. The B-cell receptor (BCR) 
is one of the main molecules involved in this cross-talk, 
playing a critical role in CLL pathogenesis and prognosis 
[3]. The importance of the BCR signaling is underlined by 
several observations. First, from the clinical standpoint, 
time to first therapy, progression free and overall survival 
in CLL is dictated in part by whether IGHV genes have 
undergone somatic hypermutation (M-CLL) or not 
(U-CLL) [1]. Of note, U-CLL cells have stronger BCR 
activation and increased proliferation, linking BCR 
signaling to clinical progression [4]. Moreover, the clinical 
relevance of BCR signaling has also been inferred by the 
prognostic impact of ZAP-70 expression. This protein 
is associated with an increased BCR signaling in CLL 
cells [5], which translates into an enhanced ability to 
respond to survival and migratory signals [6]. Finally, the 
relevance of the BCR signaling in CLL has been proved 
by the demonstration of an extraordinary clinical activity 
of several inhibitors of key downstream kinases, such as 
ibrutinib, idelalisib, duvelisib and many others [7, 8].
Signal transduction initiated by BCR activation 
leads to the recruitment, phosphorylation, and sustained 
activity of the spleen tyrosine kinase (Syk) [9]. In CLL, 
Syk has been shown to be up-regulated at both the mRNA 
and protein levels, [10] and a constitutive Syk activation 
has been described [11]. Therefore, Syk has been 
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hypothesized to be an excellent candidate for targeted 
therapy in CLL. The effect of Syk inhibition has been 
tested with fostamatinib (R406), a kinase inhibitor with 
limited specificity to Syk, demonstrating induction of 
apoptosis and blockade of chemokine-induced migration 
of CLL cells [11, 12] Fostamatinib has been clinically 
evaluated in CLL and other B cell malignancies with a 
hint of efficacy in these diseases [13, 14]. Herein, we 
presented the effectiveness of the novel, highly specific 
Syk inhibitor TAK-659 in suppressing the induction of 
survival, proliferation and migration of CLL cells by the 
microenvironment, thus providing the biological rationale 
for its clinical development in CLL.
RESULTS
BCR stimulation increases viability and 
enhances proliferation in primary CLL cells  
co-cultured with BMSC, CD40L and CpG ODN
To in vitro reproduce the microenvironment that 
CLL cells find in the proliferative centers in vivo, we 
co-cultured primary CLL cells with the BMSC cell line 
UE6E7T-2, soluble CD40L and CpG ODN which induce 
proliferation and chemoresistance in primary CLL cells 
as we have recently shown [15]. Western blot analysis 
showed that phosphorylation of Akt and ERK1/2 after 
BCR cross-linking was higher in co-cultured CLL 
cells than in cells in suspension (Figure 1A). Since the 
activation of BCR pathway induces pro-survival and 
proliferative signals in CLL cells, [4, 12, 16, 17, 18] 
we tested the effects of BCR stimulation with anti-IgM 
in CLL cell viability and proliferation in this co-culture 
system. We observed that the addition of anti-IgM for 48 
hours protected co-cultured CLL cells from undergoing 
spontaneous apoptosis (Figure 1B) (mean % of viable 
co-cultured CLL cells related to CLL cells in suspension: 
94.08 ± 20.27 without anti-IgM stimulation vs. 137.52 ± 
26.17 with anti-IgM stimulation, P < 0.05). Moreover, 
proliferative responses were already observed after 24 
hours of co-culture although a significant induction of 
Ki-67 expression was only observed after 48 hours of co-
culture with the addition of anti-IgM (Figure 1C) (mean 
% Ki-67-positive cells: 0.91 ± 0.22 in suspension vs. 3.85 
± 0.93 in co-culture, P > 0.05, or vs. 7.00 ± 1.49 in co-
culture with anti-IgM, P < 0.001).
Treatment with TAK-659 inhibits Syk activation 
and BCR signaling in co-cultured primary CLL 
cells and Burkitt’s lymphoma cells
To determine the effects of the Syk inhibitor TAK-
659 on BCR downstream signaling, we firstly used the 
Burkitt’s lymphoma cell line Ramos as a model of mature 
malignant IgM-positive B-cells. We treated Ramos 
cells with increasing doses of TAK-659 for 1 hour, and 
subsequently, we stimulated BCR with anti-IgM for 5 
minutes prior to whole protein extraction. Stimulated 
Ramos cells displayed enhanced expression of phospho-
Syk at Tyr525 and Tyr352 and phospho-ERK1/2. 
Treatment with TAK-659 was able to completely abrogate 
ERK phosphorylation induced by anti-IgM stimulation. 
However, we observed that higher doses of TAK-659 
were required to completely inhibit phosphorylation of 
Syk at the TAK-659 binding site, Tyr525, located within 
the kinase domain. Interestingly, an initial enhancement 
on phosphorylation of Syk at this site was observed with 
lower doses of TAK-659. This observation, along with 
the enhancement on phosphorylation in residue Tyr352 of 
Syk protein, an activation site within the interdomain B, 
in response to TAK-659 treatment at any dose, suggest a 
differential regulation of these sites via a positive feedback 
(Figure 2A and 2B). 
In primary CLL cells in suspension culture, TAK-
659 treatment resulted in a dose-dependent reduction in 
the phosphorylation of SykTyr525, Btk, NFκB, ERK1/2 
and STAT3 after BCR stimulation (Figure 2C and 2D). 
For robust and consistent detection of phosphorylated 
proteins, we treated cells with H2O2, a broad phosphatase 
inhibitor, as previously described [19]. Finally, in order to 
assess the effect of TAK-659 in CLL cells being stimulated 
by different players from the microenvironment we pre-
treated CLL cells with TAK-659 1 μM for 1 hour followed 
by co-culture with BMSC, CD40L and CpG ODN for 15 
minutes and subsequent BCR crosslinking for 5 additional 
minutes. An enhancement on SykTyr525 was evidenced in 
co-cultured and BCR-stimulated primary CLL cells with 
the addition of H2O2. This Syk
Tyr525 enhancement was 
inhibited by TAK-659 (Figure 2E). Phosphorylation of 
Btk, Akt, NFκB and STAT3 was also decreased after 
TAK-659 treatment, thus confirming the inhibition 
of Syk downstream signaling also in this setting. 
However, contrary to what we observed when cells 
were only stimulated by anti-IgM, the phosphorylation 
of ERK1/2 was not inhibited by TAK-659 treatment, 
reflecting persistent activation of alternative pathways 
independent from Syk in co-cultured primary CLL cells 
(Figure 2E and 2F).
Inhibition of Syk by TAK-659 induces apoptosis 
of CLL cells and abrogates BCR and co-culture-
derived survival signals
To determine whether the pro-survival effect of co-
culture and BCR stimulation might be abrogated by TAK-
659, we treated co-cultured and anti-IgM stimulated CLL 
cells with increasing doses of TAK-659. As displayed in 
Figure 3A, TAK-659 significantly reduced the viability 
of CLL cells in a dose-dependent manner, after 48 hours 
of treatment (mean % viability relative to untreated CLL 
cells for TAK-659 0.1 μM, 1 μM and 10 μM after 48 
hours: 93.51 ± 6.78 vs. 67.91 ± 8.88 vs. 63.05 ± 6.39, 
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respectively, P < 0.001). Next, to determine differences 
in the sensitivity to TAK-659 treatment according to the 
stimuli present in the co-culture system, we cultured 
primary CLL cells in 4 different conditions: in suspension, 
stimulated with anti-IgM, co-cultured with BMSC and 
stimulated with CD40 ligand along with CpG ODN and, 
co-cultured with the addition of anti-IgM. Increasing doses 
of TAK-659 were added and viability of CLL cells was 
assessed after 48 hours of treatment. We observed that the 
addition of anti-IgM stimulation to the co-culture system 
provided the greater sensitivity to TAK-659 (TAK-659 
LD50 for CLL cells in suspension: 38.14 μM [95%CI 
27.47–52.96] vs. TAK-659 LD50 for CLL cells in co-
culture and anti-IgM: 16.91 μM [95%CI 10.61–26.93], 
P = 0.006) (Figure 3B). No statistically significant 
difference was observed between dose effect curves for 
anti-IgM or co-culture alone compared to CLL cells in 
suspension although LD50 for CLL cells in suspension was 
higher (TAK-659 LD50 for CLL cells with anti-IgM: 22.04 
μM [95%CI 8.72–55.69] vs. TAK-659 LD50 for CLL cells 
in co-culture: 31.89 μM [95%CI 19.93–51.05], P > 0.05) 
(Figure 3B). We then compared the effects of TAK-659 
with those of Syk-inhibitor R406 (fostamatinib) on the 
viability of primary CLL cells. We observed that TAK-659 
resulted clearly more effective than R406 in inducing CLL 
cells apoptosis in all culture conditions (Figure 3C–3F). 
TAK-659 displayed a significantly stronger capacity to 
induce apoptosis in primary CLL cells in suspension, being 
the LD50 for TAK-659 more than 40 times lower than the 
one observed for R406 (Figure 3C). The stimulation with 
anti-IgM or the co-culture of primary CLL cells seemed 
to provide slight higher sensitivity to R406 treatment 
although not significant. However, the combination of 
anti-IgM stimulation and co-culture induced a marked 
resistance to R406 treatment that precluded the calculation 
of a LD50, whereas LD50 for TAK-659 was 16.91 μM 
(95%CI 10.61–26.93 μM) (Figure 3D).
Altogether, this data indicates a strong capacity of 
TAK-659 to block the microenvironment-derived survival 
signals and a higher efficacy in co-cultured and BCR-
stimulated CLL cells compared to cells in suspension.
TAK-659 inhibits the up-regulation of 
proliferation and activation markers induced by 
the co-culture in primary CLL cells 
To test whether TAK-659 was able to override the 
co-culture-induced proliferation described above (Figure 
1C), primary CLL cells were treated with increasing doses 
of TAK-659 for one hour and subsequently co-cultured 
for 48 hours. TAK-659 treatment inhibited co-culture-
induced proliferation in a dose-dependent manner, being 
Figure 1: BCR stimulation with anti-IgM increases viability and enhances proliferation in primary CLL cells co-cultured 
with BMSC, CD40L and CpG ODN. (A) Primary CLL cells were co-cultured with BMSC, CD40L and CpG ODN for 15 minutes and 
anti-IgM was added for 1 additional minute. Figure shows the immunoblot analysis of Akt and ERK1/2 phosphorylation from a representative 
patient. (B) Primary CLL cells were co-cultured with BMSC, CD40L, CpG ODN and anti-IgM for 24 and 48 hours. Viability was assessed 
in primary CLL cells from 9 patients by Annexin V and PI staining. (C) Mean % of Ki-67-positive cells from 9 patients was analyzed by FC. 
(*P < 0.05, ***P < 0.001, two-way ANOVA, Bonferroni’s post-test. Graph shows mean ± SEM). PV: treatment with pervanadate. 
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10 μM the TAK-659 dose at which the percentage of Ki-
67 positive CLL cells did not significantly differ from that 
in unstimulated CLL cells (Figure 4A) (mean % of Ki-67-
positive cells: 7.00 ± 1.49 in untreated controls vs. 3.39 
± 0.76 in TAK-659 0.1 μM-treated CLL cells, P < 0.01 
vs. 1.72 ± 0.20 in TAK-659 1 μM-treated CLL cells, P < 
0.01 vs. 1.27 ± 0.18 in TAK-659 10 μM-treated CLL cells, 
P < 0.001). We next assessed the effect of TAK-659 on 
CLL cell activation evaluating expression of CD86, CD69 
and CD38. CD86 and CD69 are two activation markers 
known to be upregulated in CLL cells from LN and BM 
in vivo.[4] CD38 is not only upregulated in activated 
CLL cells but also serves as prognostic marker [20, 21]. 
Co-culture of primary CLL cells induced a significant 
Figure 2: Syk inhibition by TAK-659 downregulates BCR signalling in Ramos and primary CLL cells. (A–B) 
Phosphorylation of Syk and ERK1/2 were analyzed by Western Blot in Ramos cells incubated with increasing doses of TAK-659 for 1 hour 
and stimulated with anti-IgM for 5 minutes. (C–D) Phosphorylation of Syk, Btk, NFκB, ERK1/2 and STAT3 were analyzed by Western Blot 
in primary CLL cells pre-treated with increasing doses of TAK-659 for 1 hour and stimulated with anti-IgM for 5 minutes. (E–F) Primary 
CLL cells pre-treated with increasing doses of TAK-659 for 1 hour were co-cultured with BMSC, CD40L and CpG ODN for 15 minutes 
and anti-IgM stimulated for additional 4 minutes. H2O2 3.3 mM was added for 4 minutes. Expression of phosphorylated Syk, Btk, NFκB, 
Akt, ERK1/2 and STAT3 was analyzed by western blot. PV: treatment with pervanadate
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Figure 3: TAK-659 induces higher degree of apoptosis than R406 in primary CLL cells. (A) Primary CLL cells from 12 
patients pre-treated with increasing doses of TAK-659 were cultured for 24 and 48 hours with BMSC, CD40L, CpG ODN and anti-IgM. 
Viability was assessed by Annexin V and PI staining by FC. Primary CLL cells from 26 patients pre-treated with increasing doses of 
TAK-659 were cultured for 48 hours in suspension, in co-culture, anti-IgM-stimulated or co-cultured and with anti-IgM stimulation (B); 
or pre-treated with increasing doses of TAK-659 or R406 in suspension (C), anti-IgM-stimulated (D), in co-culture (E) or co-cultured with 
anti-IgM-stimulation (F). LD50 curves for TAK-659 and R406 are plotted on a logarithmic scale. LD50 for every treatment cohort were 
calculated and compared (Two-way ANOVA, Bonferroni’s post-test. Graph shows mean ± SEM).
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increase in the expression of these activation markers. 
Interestingly, Syk inhibition by TAK-659 resulted in 
marked downregulation of the expression of CD86, CD69, 
and CD38 in a dose-dependent manner though the degree 
of downregulation of CD69 was smaller compared to that 
of CD86 or CD38 (Figures 4B, 4C, 4D and 4E). 
TAK-659 inhibits chemotaxis toward BMSC, 
CXCL12 and CXCL13 in primary CLL cells
In addition to survival and proliferative signals, BCR 
signaling also promotes the homing of CLL cells to the 
BM and the LN, thus facilitating their access to favorable 
environments. This is mainly mediated by enhancing the 
response to CXCR4 and CXCR5 [12, 22, 23, 24]. To evaluate 
the impact of Syk inhibition by TAK-659 on the ex vivo 
chemotaxis of CLL cells, we analyzed the ability of CLL 
cells to migrate toward CXCL12, CXCL13 and the BMSC 
cell line HS-5 by performing transmigration assays using bare 
polycarbonate membranes. Treatment of primary CLL cells 
with TAK-659 0.1 μM for 1 hour resulted in a strong reduction 
of the migratory capacity toward CXCL12, CXCL13 and the 
BMSC cell line, HS-5 (Figures 5A, 5B and 5C).
TAK569 abrogates microenvironment-induced 
chemoresistance 
As we previously described, [15, 25] the co-culture 
of CLL cells with BMSC, CD40L and CpG ODN induces 
marked resistance to fludarabine and bendamustine in 
primary CLL cells. To test whether the addition of TAK-659 
might overcome this co-culture-induced chemoresistance, 
we assessed the effects of the combination of TAK-659 with 
fludarabine. For that purpose, we compared the viability 
rates after treatment with increasing doses of fludarabine 
with or without 0.1 μM TAK-659 in primary CLL cells 
co-cultured with BMSC, CD40L and CpG ODN with 
the addition of anti-IgM. We chose this dose of TAK-659 
according to the significant effects in terms of proliferation, 
activation, migration and inhibition of BCR signaling 
mentioned before. In line with our previous observations, 
[15] this co-culture system inhibited fludarabine-induced 
apoptosis in primary CLL cells. Interestingly, we observed 
that this co-culture-induced chemoresistance was markedly 
reverted by the addition of TAK-659 (Figure 6A). 
Subsequent calculation of the cooperative index between the 
two drugs at different fludarabine concentrations indicates 
that simultaneous treatment with TAK-659 and fludarabine 
synergistically induces apoptosis in co-cultured CLL cells 
independently from fludarabine dose (Figure 6D).
TAK-659 synergizes with other BCR inhibitors 
in co-cultured CLL cells
To investigate the effects of the combination of 
TAK-659 with other BCR inhibitors we treated primary 
CLL cells with 0.1 μM TAK-659 combined with 
increasing doses of the Btk inhibitor, ibrutinib, and the 
PI3K delta-specific isoform inhibitor, idelalisib, and 
compared their viability rates. We observed that apoptosis 
was significantly increased by TAK-659 in ibrutinib-
treated co-cultured CLL cells (Figure 6B). Interestingly, 
cooperative index values revealed that TAK-659 strongly 
potentiated ibrutinib cytotoxicity especially at 1µM of 
ibrutinib in co-cultured CLL cells (Figure 6D). Although 
we observed no significant difference in the induction 
of apoptosis between treatment with idelalisib as single 
agent and in combination with TAK-659 (Figure 6C), 
synergic cytotoxicity was also demonstrated with the 
combination. Similarly to the combination of TAK-659 
with ibrutinib, the combination with idelalisib displayed 
highest synergistic effect (lowest cooperative values) at 
the lowest idelalisib dose tested (Figure 6D).
Sequential treatment with TAK-659 strongly 
enhances long-term cytotoxicity in ibrutinib-
treated CLL cells 
Despite the incontestable success in the treatment 
of CLL shown so far, a progression rate of 5.3% has been 
already reported in patients under ibrutinib treatment 
[7, 8]. Resistance to ibrutinib has been related to the 
overgrowth of subclones with BTK or PLCg2 mutations, 
resulting in reactivation of the BCR pathway [26]. To test 
whether the upstream inhibition of BCR signaling with 
TAK-659 could have a cytotoxic effect in cells that have 
been under the pressure of ibrutinib treatment we designed 
an experimental approach using a long-term culture system 
with CD40-stimulated primary CLL cells. In that culture 
system we treated CLL cells with ibrutinib for 4 days and 
subsequently, TAK-659 was added. We used CLL cells 
treated with either ibrutinib or TAK-659 alone as control. 
Interestingly, we observed that CD40-stimulated primary 
CLL cells persisted insensitive, in terms of cytoxicity, to 1 
μM ibrutinib treatment along time. By contrast, sequential 
treatment with TAK-659 efficiently decreased the viability 
of these ‘ibrutinib-resistant’ primary CLL cells (mean 
% viability relative to untreated CLL cells for ibrutinib, 
TAK-659 or ibrutinib and TAK-659 after 14 days: 85.45 
± 32.10 vs. 23.61 ± 11.62 vs. 17.89 ± 1.43, respectively, 
P < 0.05; and after 18 days: 165.22 ± 94.10 vs. 0.89 ± 0.01 
vs. 3.92 ± 3.20, respectively, P < 0.001) (Figure 6E).
TAK-659 does not inhibit TCR signaling and 
molecular features of T cell activation in primary 
T cells from patients with CLL
The primary aminoacid sequence of Syk is 
homologous to that of ZAP-70, the expression of which 
is mostly confined to T and natural killer (NK) cells [27]. 
Given the striking homology between these two Syk 
family kinases we hypothesized that TAK-659 might be 
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Figure 4: Treatment with TAK-659 effectively abrogates the co-culture-induced proliferation and activation of primary 
CLL cells. Primary CLL cells from 10 patients pre-treated with increasing doses of TAK-659 were cultured with BMSC, CD40L, CpG 
ODN and anti-IgM for 48 hours and the expression of Ki-67 (A), CD86 (B), CD69 (C) and CD38 (D) was analyzed by FC. (E) Histograms 
from a representative patient. (*P < 0.05, **P < 0.01, ***P < 0.001, two-way ANOVA, Bonferroni’s post-test. Graph shows mean ± SEM).
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a potential ZAP-70 inhibitor. This might have crucial 
consequences such as suppression of T cell-based immune 
responses or antibody-dependent NK-cell mediated 
cytotoxicity (ADCC), as shown for ibrutinib inhibiting Itk 
protein which has sequence and functional homology to 
Btk protein [28, 29]. 
To investigate the effects of TAK-659 on T cells, we 
firstly determined the effects on anti-CD3-induced TCR 
signalling in Jurkat T cells. Immunoblot data revealed that 
phosphorylation of ZAP-70Tyr319, ZAP-70Tyr493, Itk, Akt and 
ERK1/2 were not affected by the treatment with TAK-659 
(Figure 7A). Further, we evaluated the apoptosis rate in 
the CD3+ cells obtained from CLL patients; these cells 
were cultured in our co-culture system and pre-treated 
with increasing doses of TAK-659. In contrast to primary 
CLL cells, we found that the co-culture did not modify the 
viability of primary T cells and that the addition of TAK-
659 did not induce apoptosis in these cells (Figure 7B). We 
also analyzed the effects of TAK-659 on T cell activation 
by determining the expression of the activation markers 
CD69 and CD38 by FC. We observed that culturing T cells 
in our co-culture system induced the expression of both 
molecules and that this upregulation was not modified 
after TAK-659 treatment (Figures 7C, 7D and 7E).
DISCUSSION
Successful targeting of tyrosine kinases that are 
crucial for BCR signaling has been one of the major 
recent breakthroughs in the treatment of patients with 
B-cell malignancies, particularly CLL. Syk protein has 
a crucial role in transmitting signaling from the BCR 
and from other receptors, such as CXCR4, providing it 
with an outstanding relevance as a therapeutic target 
for CLL [10, 11]. In this sense, targeting Syk has been 
previously explored using fostamatinib, [11, 10, 12, 30] 
although some activity was reported in a phase 2 study 
in NHL and CLL, [13] further clinical development in 
B-cell malignancies has not been reported. Recently, 
entospletinib (GS-9973), has been, demonstrated to 
have clinical activity and acceptable toxicity in patients 
with relapsed or refractory CLL [31]. TAK-659, a new 
Figure 5: Syk inhibition by TAK-659 inhibits chemotaxis of primary CLL cells toward CXCL12, CXCL13 and BMSC. 
Primary CLL cells from 6 patients were assayed for chemotaxis toward CXCL12, CXCL13 and the BMSC cell line HS-5 for 4 hours after 
incubation for 1 hour with TAK-659. (*P < 0.05, **P < 0.01, paired T-test. Wilcoxon post-test).
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Syk inhibitor, has recently shown antitumor activity in 
lymphoma xenograft models [32] and in diffuse large B 
cell lymphoma patients according to preliminary data from 
the first-in-human phase 1 clinical trial [33].
In the present study, TAK-659 was able to 
completely block the anti-IgM-induced phosphorylation 
of Btk, NFκB and ERK1/2. Of note, TAK-659 treatment 
also led to the inhibition of STAT3Tyr705 phosphorylation, as 
Figure 6: The combination of TAK-659 with fludarabine, ibrutinib or idelalisib synergistically induces apoptosis in 
proliferative CLL cells. Primary CLL cells from 12 patients were pre-treated with 0.1 μM TAK-659 and increasing doses of fludarabine 
(A), ibrutinib (B) or idelalisib (C) for 1 hour and co-cultured for 48 hours. LD50 for every treatment cohort were calculated and compared 
(*P < 0.05, **P < 0.01, ***P < 0.001, two-way ANOVA, Bonferroni’s post -test. Graph shows mean ± SEM). (D) Calculated combination 
index values are plotted. (E) Primary CLL cells from 6 patients were pre-treated with 1 μM ibrutinib or 1 μM TAK-659 and cultured with 
CD40L 1 μg/mL. After 4 days, 1 μM TAK-659 was added to ibrutinib-treated cells. Viability of primary CLL cells was analyzed by Annexin 
V and PI staining by FC at the indicated time points. (*P < 0.05, ***P < 0.001, paired T-test. Wilcoxon post-test).
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Figure 7: TAK-659 does not inhibit TCR downstream signaling or expression of activation molecules in T cells. 
(A) Jurkat cells were incubated with 0.1 μM TAK-659 for 1 hour and stimulated with anti-CD3 for 1 minute. Expression of phospho-
proteins was analyzed by western blot. Jurkat cells treated with pervanadate (PV) were used as positive controls. (B) PBMC from 10 patients 
diagnosed with CLL were incubated with increasing doses of TAK-659 for 1 hour and cultured in suspension or in co-culture with BMSC, 
CD40L, CpG ODN and anti-IgM for 48 hours. Viability of T cells was assessed by Annexin V and PI staining in CD3+ cells by FC. (C–D) 
PBMC from 10 patients diagnosed with CLL were incubated with 0.1 μM TAK-659 for 1 hour and cultured in suspension or in co-culture 
with BMSC, CD40L, CpG ODN and anti-IgM for 48 hours. The expression levels of CD69 and CD38 were analyzed in CD19-/CD3+ cells 
by FC. (E) Histograms for the expression of CD69 and CD38 along with dot-plots for the expression of Annexin V and PI in CLL cells 
cultured in suspension or in co-culture with anti-IgM with or without TAK-659 from a representative patient are shown. (*P < 0.05, **P < 
0.01, paired T-test, Wilcoxon post-test. Graph shows mean ± SEM).
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recently described with fostamatinib [34]. Moreover, we 
observed persistence of phosphorylation of SykTyr352 and 
ERK1/2 after TAK-659 treatment, suggesting the existence 
of molecular feedback loops that would activate SykTyr352 
and alternative signaling pathways, such as CXCR4, 
responsible for ERK1/2 activation when BCR signaling is 
inhibited. In this regard, SykTyr352 phosphorylation through 
Lyn activation in a feedback response to Syk inhibition by 
fostamatinib has been previously described [35].
Clinically, BCR inhibitors cause CLL cell 
redistribution from tissues into the PB [7, 36]. Reduced 
CLL cell adhesion to stromal cells might promote their 
mobilization to the PB where a reduced responsiveness 
to CXCL12 and CXCL13 might block CLL cell tissue 
homing. In this report we have demonstrated that TAK-
659 is able to effectively impair CLL cell migration 
toward CXCL12, CXCL13 and the BMSC cell line HS-5, 
in line with previous studies with other BCR inhibitors 
[37, 38].
Herein, we have also shown how TAK-659 is able 
to efficiently induce apoptosis in primary CLL cells 
preferentially in proliferative culture conditions. As seen 
with other kinase inhibitors like ibrutinib or idelalisib, 
[37–40] TAK-659 requires doses at the micromolar range 
to achieve significant cytotoxicity in CLL cells despite its 
inhibitory dose 50 for enzymatic activity is 3.2 nM [32].
The diverse signaling from the microenvironment is 
also involved in the induction of resistance to fludarabine. 
Herein, we show that TAK-659 is able to overcome this 
microenvironment-induced resistance to fludarabine, 
and that the combination with ibrutinib or idelalisib 
synergistically decreased CLL cell viability. Significant 
induction of apoptosis was specifically seen in co-cultured 
CLL cells suggesting that the difficulty in eradicating this 
CLL cell compartment might be successfully targeted with 
combination treatment strategies. In this sense, cross-talk 
between signaling pathways and feedback loops induced 
by continuous inhibition of a single target might drive 
resistance and have impact on the efficacy of single agent 
therapy. Therefore, we foresee a near future where the 
simultaneous or sequential inhibition of multiple CLL cell 
signaling pathways might progressively become relevant 
for overcoming resistance to single agents. Further, 
our experiments with extended culture of primary CLL 
cells treated with ibrutinib, TAK-659 or the sequential 
combination of both drugs suggest that combinations of 
different BCR signaling inhibitors, may be an efficient 
therapeutical approach. Recently, ibrutinib has been shown 
to irreversibly bind to and inhibit the Btk homologue Itk 
protein, therefore inhibiting Th2 activation after TCR 
stimulation. Moreover, Itk inhibition by ibrutinib also led 
to antagonize anti-CD20 antibodies-dependent NK-cell 
mediated cytotoxicity, therefore having a negative interaction 
that should be considered when designing combination 
therapies including these two types of drugs. Similar effects 
have been observed with idelalisib [28, 41, 29]. In contrast, 
we showed that TAK-659 treatment does not inhibit the Syk 
homologue ZAP-70 since downregulation of TCR-derived 
signaling or inhibition of T cell activation were not observed. 
These results are in agreement with previous kinase activity 
assays that showed that TAK-659 IC50 for inhibiting ZAP-70 
was 87 nM compared to 3.2 nM for inhibiting Syk [32]. 
In conclusion, our work contributes to the 
establishment of Syk inhibition using TAK-659 as a 
rational therapeutic strategy for patients with CLL.
MATERIALS AND METHODS
Isolation and culture of primary CLL cells
Peripheral blood mononuclear cells (PBMC) from 
26 patients diagnosed with CLL were isolated by Ficoll-
Paque Plus (GE Healthcare, Buckinghamshire, United 
Kingdom) density gradient and stored in liquid nitrogen 
until analysis. Only samples with ≥ 85% of CD19+/CD5+ 
cells CLL cells, as assessed by flow cytometry (FC), 
were included in the study. A written informed consent 
was obtained from all patients in accordance with the 
Declaration of Helsinki, and the study was approved by 
the local ethical committee. 
Cell lines
The UE6E7T-2 and HS-5 human bone marrow 
stromal cells (BMSC) cells line were obtained from Riken 
Cell Bank (Ibaraki, Japan) and ATCC (Manassas, VA, 
USA), respectively. Cells were cultured at 37ºC in 5% 
CO2 atmosphere in Dulbecco’s Modified Eagle Medium 
(DMEM; Gibco, Carbbad, CA, USA) supplemented with 
2 mM L-glutamine, 10% heat-inactivated fetal bovine 
serum (FBS) and 50 μg/mL penicillin/streptomycin. The 
T-cell acute lymphoblastic leukemia cell line Jurkat and 
the Burkitt’s lymphoma cell line Ramos were obtained 
from ATCC and were cultured in RPMI 1640 medium 
supplemented with 2 mM L-glutamine, 10% heat-
inactivated FBS and 50 μg/mL penicillin/streptomycin. All 
cell lines were obtained more than 6 months before the 
date of the experiments, and they were not authenticated 
by the authors.
Co-culture conditions
Following the method we previously described, 
[25] BMSCs were seeded at a concentration of 1.5 × 104 
cells/mL in 24-well plates and incubated for 24 hours to 
allow cells to adhere. CLL cells were cultured at a ratio 
of 100:1 (1.5x106cells/mL) on confluent layers of BMSC 
in RPMI-10%FCS supplemented with 1 μg/mL CD40L 
(Peprotech, London, United Kingdom) and 1.5 μg/mL 
CpG ODN (ODN2006; Invivogen, San Diego, CA, USA). 
Cross-linking of BCR on primary CLL cells and Ramos 
cells was performed with 10 μg/mL goat anti-human IgM 
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F(ab’)2 fragment (Invitrogen, Carlsbad, CA, USA). At the 
indicated time points, CLL cells were harvested by gently 
washing off, leaving the adherent stromal cell layer intact.
Flow cytometry
Intracellular staining of Ki-67 was performed using a 
fluorescein isothiocyanate (FITC)-labeled antibody against 
Ki-67 (Becton Dickinson, Franklin Lakes, NJ, USA) after 
fixation and permeabilization using the BD Intrasure 
kit (Becton Dickinson) following the manufacturer’s 
instructions. Surface staining of cells was performed using 
the following monoclonal antibodies conjugated with the 
indicated fluorochrome: CD19-phycoerythrin (PE) and 
CD5-allophycocyanine (APC) (Becton Dickinson).
Expression of CD69, CD38 and CD86 in CD19+/
CD5+ and CD3+ cells was assessed using the following 
antibodies: CD19-energy coupled dye (ECD), CD5-
phycoerythrincyanine 5.5 (PC5.5) (Beckman Coulter, 
Brea, CA, USA), CD38-PE (EBioscience, San Diego, 
CA, USA), CD3-PE-cyanine 7 (Cy7), CD69-APC and 
CD86-APC (Becton Dickinson). Cells were acquired in a 
NaviosTM cytometer (Beckman Coulter, Brea, CA, USA) 
and the results were analyzed using the FCS Express 4 
software (De Novo Software, Los Angeles, CA, USA).
Western blot analysis
Ramos, Jurkat and primary CLL cells treated with 
the phosphatase-inhibitor pervanadate (3 mM H2O2/ 1 
mM NaVO4) for 5 minutes or 3.3 mM H2O2 for 4 minutes 
at 37ºC were used as positive controls for phospho-
proteins. Whole cell protein extracts were prepared from 
10 × 106 cells using 50 μL lysis buffer containing 20 mM 
Tris(hydroxymethyl)aminomethane (Tris) pH 7.4, 1 mM 
EDTA, 140 mM NaCl, 1% NP-40 supplemented with 
2 mM sodium vanadate and protease inhibitor cocktail 
(Sigma-Aldrich, San Louis, MO, USA) for 1 hour at 4ºC. 
Protein concentration was determined using the Bio-
Rad protein assay (Bio-Rad, Hercules, CA, USA). Equal 
amounts of denatured protein were resolved by 10% 
SDS-PAGE and transferred to Immobilon-P membranes 
(Millipore, Bedford, MA, USA). Membranes were 
blocked for 1 hour at room temperature (RT) in 3% milk/
TBS-T. Membranes were incubated overnight at 4ºC with 
primary antibodies against phospho-SykTyr352/phosho-ZAP-
70Tyr319, phospho-ZAP-70Tyr493, phospho-AktSer473, phospho-
ERK1/2Thr202/Tyr204, phospho-STAT3Tyr705, Akt, ERK1/2 and 
STAT3 (Cell Signaling Technology), phospho-NFκB 
p65Ser536, Syk and ZAP-70 (Santa Cruz Biotechnologies, 
Dallas, TX, USA), phospho-BtkTyr551/phospho-ItkTyr511, Btk 
and Itk (BD Biosciences), phospho-SykTyr525 and GAPDH 
(Abcam, Cambridge, United Kingdom), and NFκB p65 
(Chemicon, Millipore). Immunodetection was done with 
the corresponding IgG HRP-linked secondary antibodies 
(Dako North America, Glostrup, Denmark), and the ECL 
chemiluminescence detection system (GE Healthcare). 
Reagents
TAK-659 (kindly provided by Takeda 
Pharmaceutical International Co.), fludarabine (Sigma), 
ibrutinib, idelalisib and R-406 (Selleckchem, Houston, 
TX, USA) were dissolved in DMSO and stored at –20ºC.
Assessment of apoptosis
Apoptosis was assessed analyzing the binding of 
annexin V-FITC and the incorporation of propidium iodide 
(PI) by FC. Annexin V/PI double negative cells were 
considered viable cells. Staining was performed according 
to the manufacturer’s instructions using the annexin 
V-FITC apoptosis detection kit (Bender Medsystems, 
Vienna, Austria). 
Chemotaxis assays
Migration toward the chemokines CXCL12 and 
CXCL13, and to the human BMSC cell line HS-5 was 
determined in primary cells from 6 patients with CLL by 
using a transwell migration assay across bare polycarbonate 
membranes (Corning Incorporated, Corning, NY, USA). 
A total of 100 μL of RPMI-0.5% bovine serum albumin 
(BSA) containing 1.5x106 CLL cells were pre-incubated 
for 1 hour with TAK-659 before they were added to the 
top chamber of a 6.5-mm-diameter transwell culture insert 
with a pore size of 5 μm. Inserts were then transferred into 
wells containing 600 μL RPMI-0.5% BSA with or without 
200 ng/mL CXCL12 or 1 μg/mL CXCL13. Cells were 
allowed to migrate toward the lower chamber for 4 hours 
at 37ºC in 5% CO2. To determine migration of CLL cells 
toward BMSCs, 1.5 × 104 HS-5 cells were seeded and 
cultured overnight with 600 μL DMEM-10% FBS on the 
lower chamber. CLL cells were allowed to migrate for 
24 hours at 37ºC in 5% CO2. The number of CLL cells 
in lower chambers was then determined by FC. The 
migration index was calculated as the number of CLL cells 
transmigrating with chemokine or stromal cells divided by 
the number of transmigrating cells with control medium only.
Statistical analysis
Results are expressed as the mean ± standard 
error of the mean (SEM) of at least three independent 
experiments. The statistically significant difference 
between groups was analyzed using the Mann-Whitney 
test or one or two-way ANOVA (t test), and P < 0.05 was 
considered significant. Lethal dose 50 (LD50) values were 
calculated with GraphPad Prism software version 5.0 
(San Diego, CA, USA). Chou-Talalay method was used 
for synergy quantification [42]. Analyses were performed 
using the biostatistics software package SPSS version 22 
(IBM, Chicago, IL, USA). Results were graphed with 
GraphPad Prism software.
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